Association of Regulatory T Cells with Diabetes Type-1 and Its Renal and Vascular Complications Based on the Expression of Forkhead Box Protein P3 (FoxP3), Helios and Neurophilin-1
,
Abstract
In recent years, it has been recognized that regulatory T cells (Tregs) play a critical role in maintaining immune tolerance. Moreover, the expression of two markers named Helios and neurophilin-1 (NRP-1) has been highlighted in such cells. Helios, an intracellular transcription marker, largely differentiates twomost operative sub group of Tregs, namely naturally occurring (nTreg) and induced (iTreg) Tregs, and NRP-1 is reckoned as a membranous activity marker of Tregs. We aimed to count peripheral mononuclear cells expressing such markers in a group of type 1 diabetes patients to elucidate the possible role of Tregs in the pathogenesis of such disease and its complications. Blood samples from 61 adult patients with type 1 diabetes and 61 sex and age-matched healthy controls were tested to count two types of Tregs, namely naturally occurring and inducible types, according to the expression of cell surface markers of CD4/CD25/CD47–FITC/PE/APC and intracellular markers of FoxP3/Helios–PE-CY5/eFlour450 by flow cytometry, respectively.We also investigated the relation between expression of such markers with HbA1c, urine albumin/creatinine ratio (UACR), and common carotid intima thickness (CIMT). The circulatory frequency of both Helios+ and Helios- T-cells were significantly decreased in patients compared to those in healthy controls (p<0.001). There was also a significant decrease in circulatory frequency of Helios+ NRP-1+ and Helios- NRP-1+ cells in the patients compared to controls (p=0.029). According to expression of Helios and NRP-1 markers, the number and function of both Tregs were decreased in diabetic patients. Moreover, the neurophilin expression was inversely associated with complications of type 1 diabetes.
Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005; 54(1):92-9.
2. Kuhn C, Besançon A, Lemoine S, You S, et al. Regulatory mechanisms of immune tolerance in type 1 diabetes and their failures. J Autoimmun 2016;71:69-77.
3. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008; 223(1):371-90.
4. Lan Q, Fan H, Quesniaux V, Ryffel B, Liu Z, Zheng SG. Induced Foxp3+ regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? J Mol Cell Biol 2012; 4(1):22-8.
5. Wong FS, Dayan CM. Regulatory T cells in autoimmune endocrine diseases. Trends Endocrinol Metab 2008; 19(8):292-9.
6. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012; 209(10):1713-22.
7. Zhou H, Zhang L, Tong L, Cai M, Guo H, Yang C, et al. editors. Expression of neuropilin-1 in kidney graft biopsies: what is the significance? Transplant Proc 2007; 39(1):81-3.
8. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3(3):253-7.
9. Geiger TL, Tauro S. Nature and nurture in Foxp3+ regulatory T cell development, stability, and function. Hum Immunol 2012; 73(3):232-9.
10. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133(5):775-87.
11. Meyerson HJ, Blidaru G, Edinger A, Osei E, Schweitzer K, Fu P, et al. NRP-1/CD304 Expression in Acute Leukemia. Am J Clin Pathol 2012; 137(1):39-50.
12. Pan Q, Chanthery Y, Liang W-C, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer cell 2007; 11(1):53-67.
13. Chen H, He Z, Bagri A, Tessier-Lavigne M. Semaphorin–neuropilin interactions underlying sympathetic axon responses to class III semaphorins. Neuron 1998; 21(6):1283-90.
14. Kikutani H, Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol 2003; 3(2):159-67.
15. Lim AY, Price P, Beilharz MW, French MA. Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy. Immunol Cell Biol 2006; 84(6):530-6.
16. Lin X, Chen M, Liu Y, Guo Z, He X, Brand D, et al. Advances in distinguishing natural from induced Foxp3 (+) regulatory T cells. Int J Clin Exp Pathol 2013; 6(2):116-23.
17. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184(7):3433-41.
18. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358(9277):221-9.
19. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells–they’re back and critical for regulation of autoimmunity! Immunol Rev 2001; 182(1):149-63.
20. Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new" speed congenic" stock of NOD. Ig mu null mice. J Exp Med 1996; 184(5):2049-53.
21. Visperas A, Vignali DA. Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them? J Immunol 2016; 197(10):3762-70.
22. Gitelman SE, Bluestone JA. Regulatory T cell therapy for type 1 diabetes: May the force be with you. J Autoimmun 2016; 71:78-87.
23. Du W, Shen Y-W, Lee W-H, Wang D, Paz S, Kandeel F, et al. Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals. PloS one 2013; 8(2):e56209.
24. Bruder D, Probst‐Kepper M, Westendorf AM, Geffers R, Beissert S, Loser K, et al. Frontline: Neuropilin‐1: asurface marker of regulatory T cells. Eur J Immunol 2004; 34(3):623-30.
25. Roncarolo M-G, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7(8):585-98.
26. She Y, Gong W, Liu Z, Hu C, Han S. Detection Th1/Treg cells and serum cytokines in fulminant type 1 diabetes. Int J Clin Exp Pathol 2016; 9(10):10824-32.
| Files | ||
| Issue | Vol 17, No 2 (2018) | |
| Section | Original Article(s) | |
| Keywords | ||
| Forkhead box protein P3 (FoxP3) Helios Neuropilin-1 Regulatory T cells Type 1 diabetes | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
